AMSBIO’s latest Deubiquitinating (DUB) enzyme assay kits offer lab managers a streamlined solution for profiling enzyme activity and screening inhibitors. These 96-well formatted kits arrive ready-to-use, eliminating the need for reagent prep and reducing assay setup time.
Designed with reproducibility and throughput in mind, the kits feature fluorophore-labeled ubiquitin derivatives, enabling high-sensitivity detection of DUB activity. Researchers can perform either kinetic or endpoint analysis in purified or cellular systems, making the kits adaptable for diverse workflows.
Tailored for key disease-relevant enzymes such as BAP1, USP7, and UCHL1, these kits help labs advance their research in oncology, neurology, and immunology while maintaining operational efficiency.
Benefits for lab managers:
- Reduces assay setup time and human error
- Enhances workflow efficiency with ready-to-use format
- Broad compatibility with standard plate readers
- Supports research in cancer, neurodegeneration, and immunity
- Suitable for academic, biotech, and pharma labs
- Enables both screening and mechanistic studies
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. The original press release was provided by AMSBIO.
